ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,955.86
0.65%
Dow Jones
43,943.78
1.23%
US Dollar vs MXN
20.41873
0.68%
Brent Oil
73.935
1.50%
Bitcoin
98,552.99
4.46%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acasti Pharma Inc (ACST)

  7. Acasti Pharma Inc (ACST) Noticias

ACST

Acasti Pharma (ACST)

Acasti Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ACST
FechaHoraFuenteTítuloSímboloCompañía
28/10/202407:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACSTAcasti Pharma Inc
15/10/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACSTAcasti Pharma Inc
08/10/202406:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACSTAcasti Pharma Inc
08/10/202406:16Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACSTAcasti Pharma Inc
08/10/202406:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ACSTAcasti Pharma Inc
06/09/202415:07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACSTAcasti Pharma Inc
09/08/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACSTAcasti Pharma Inc
07/08/202415:14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACSTAcasti Pharma Inc
31/07/202406:22Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:ACSTAcasti Pharma Inc
11/07/202410:16Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
10/07/202420:10Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACSTAcasti Pharma Inc
09/07/202419:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
10/05/202415:11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
08/05/202418:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
10/10/202306:40Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACSTAcasti Pharma Inc
06/10/202315:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACSTAcasti Pharma Inc
25/08/202315:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACSTAcasti Pharma Inc
10/07/202308:00PR Newswire (US)Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH PatientsNASDAQ:ACSTAcasti Pharma Inc
07/07/202307:00PR Newswire (US)Acasti Pharma Announces 1-for-6 Reverse Stock SplitNASDAQ:ACSTAcasti Pharma Inc
05/07/202308:00PR Newswire (US)Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023NASDAQ:ACSTAcasti Pharma Inc
23/06/202306:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACSTAcasti Pharma Inc
23/06/202306:00PR Newswire (US)Acasti Pharma Reports Fiscal Year 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
22/06/202308:00PR Newswire (US)Acasti Announces Appointment of New Scientific Advisory Board MembersNASDAQ:ACSTAcasti Pharma Inc
26/05/202314:07Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ACSTAcasti Pharma Inc
17/05/202308:00PR Newswire (US)Acasti to Participate in the Lytham Partners Spring 2023 Investor ConferenceNASDAQ:ACSTAcasti Pharma Inc
08/05/202306:00PR Newswire (US)Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025NASDAQ:ACSTAcasti Pharma Inc
05/04/202316:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACSTAcasti Pharma Inc
04/04/202307:01PR Newswire (US)Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDNASDAQ:ACSTAcasti Pharma Inc
04/04/202307:00PR Newswire (US)Acasti Announces Appointment of Prashant Kohli as CEONASDAQ:ACSTAcasti Pharma Inc
30/03/202307:30PR Newswire (US)Acasti Pharma Inc. Announces the Resignation of a DirectorNASDAQ:ACSTAcasti Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ACST

Su Consulta Reciente

COIN
DOGEUSD
Dogecoin
SPI
SP500
S&P 500
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
FX
EURMXN
Euro vs MXN
AMEX
SPY
SPDR S&P 500
COIN
ADAUSD
Cardano
COIN
AVAXUSD
Avalanche
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
COIN
XRPUSD
Ripple
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados